Bile Duct Diseases: Clinical Trials

483 completed, 189 unknown, 140 recruiting, 89 terminated. 246 Phase 2, 241 Not applicable, 131 Phase 1, 124 Phase 3, 49 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	246	Completed 120, Terminated 44, Recruiting 24, Unknown 24, Not yet recruiting 12, Withdrawn 11, Active not recruiting 10, Enrolling by invitation 1
Not applicable	241	Completed 111, Unknown 61, Recruiting 24, Terminated 19, Not yet recruiting 11, Active not recruiting 7, Withdrawn 7, Enrolling by invitation 1
Phase 1	131	Completed 88, Recruiting 17, Unknown 8, Terminated 7, Withdrawn 5, Not yet recruiting 4, Active not recruiting 1, Suspended 1
Phase 3	124	Completed 58, Unknown 20, Recruiting 13, Active not recruiting 11, Terminated 11, Withdrawn 7, Not yet recruiting 3, Enrolling by invitation 1
Phase 4	49	Unknown 20, Completed 17, Recruiting 6, Terminated 6
Early Phase 1	10	Completed 4, Recruiting 3, Unknown 2, Active not recruiting 1

Follow Bile Duct Diseases: new trials by email Literature Review of Bile Duct Diseases trials Research Report on Bile Duct Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer	Not applicable	Not yet recruiting	Case Comprehensive Cancer Center	20	2027-01-01	2026-08-05
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease	Phase 2	Not yet recruiting	Mayo Clinic	15	2026-11-01	2026-09-28
J-LINX: Japan LINerixibat eXtension Study Linerixibat - Pruritus	Phase 3	Not yet recruiting	GlaxoSmithKline	40	2026-10-09	2026-10-06
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC	Phase 1 / Phase 2	Recruiting	Full-Life Technologies UK Limited	208	2026-10-01	2026-10-16
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis Oral Vancomycin - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)	Phase 2	Not yet recruiting	Tampere University Hospital	140	2026-10-01	2026-09-10
Tolerability of Enteral NAC in Infants N-Acetylcysteine - Biliary Atresia	Phase 1	Not yet recruiting	Sanjiv Harpavat	12	2026-10-01	2026-03-04
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis Seladelpar, PTM Seladelpar, Cilofexor Dose B - Primary Biliary Cholangitis	Phase 2	Not yet recruiting	Gilead Sciences	132	2026-10-01	2026-09-25
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope Endoscopic ultrasound examination - Pancreatic Disease, Pancreatic Cancer	Not applicable	Recruiting	Orlando Health, Inc.	140	2026-10-01	2026-10-20
Individualized Drainage Strategy Based on Risk Stratification in Children Undergoing Surgery for Choledochal Cyst: A Prospective Randomized Controlled Trial Robot-Assisted Roux-en-Y Hepaticojejunostomy with Drainage Management - Children Following Robot-assisted Roux-en-Y Hepaticojejunostomy for Choledochal Cysts, Choledochal Cyst	Not applicable	Not yet recruiting	Xueqiang Yan	80	2026-09-01	2026-09-17
Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia Umbilical Cord-Mesenchymal Stem Cells (UC-MSC), Kasai Portoenterostomy - Biliary Atresia, Kasai Operation	Phase 1	Recruiting	Dr Cipto Mangunkusumo General Hospital	40	2026-09-01	2026-09-09
Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis Standard background therapy, Placebo, hUC-MSC Dose Level 1 - Primary Biliary Cholangitis	Phase 1 / Phase 2	Not yet recruiting	Beijing 302 Hospital	68	2026-08-31	2026-08-31
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy Saroglitazar Magnesium 1 mg, Placebo - Primary Biliary Cholangitis	Phase 3	Recruiting	Zydus Therapeutics Inc.	90	2026-08-11	2026-09-15
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study FGFR Inhibitor, IDH1 mutation inhibitor, KRAS mutation inhibitor - Bile Duct Carcinoma, Cholangiocarcinoma	Phase 2	Not yet recruiting	Zhejiang University	240	2026-08-10	2026-07-28
Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation Fecal Fat - Exocrine Pancreatic Insuficiency		Recruiting	Digestive Care, Inc.	30	2026-08-03	2026-10-13
Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progression PBC		Not yet recruiting	Beijing Municipal Administration of Hospitals	300	2026-08-01	2026-08-04
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy Elafibranor - Pregnancy Related		Recruiting	Ipsen	3	2026-07-29	2026-10-06
A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment Alagille Syndrome		Recruiting	Ipsen	30	2026-07-10	2026-10-01
LEOPARD Prospective Validation Cohort 1 Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking - Decompensated Liver Cirrhosis, Primary Biliary Cholangitis		Recruiting	Assistance Publique - Hôpitaux de Paris	630	2026-07-07	2026-07-29
Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC) Primary Biliary Cholangitis (PBC)		Enrolling by invitation	Stanford University	30	2026-07-01	2026-06-11
The Value of Spleen Stiffness Measurement in Patients With PBC Spleen stiffness measurement - Primary Biliary Cholangitis, Spleen Stiffness	Not applicable	Not yet recruiting	Universitair Ziekenhuis Brussel	125	2026-07-01	2026-05-01

Showing 20 of 1041. Sign in to see all of them.

Narrower conditions

Bile Duct Neoplasms (251)  ·  Liver Cirrhosis, Biliary (212)  ·  Cholangitis, Sclerosing (146)  ·  Cholestasis (138)  ·  Pancreatic Neoplasms (134)  ·  Choledocholithiasis (107)  ·  Gallbladder Neoplasms (105)  ·  Cholangiocarcinoma (98)  ·  Biliary Atresia (75)  ·  Cholangitis (74)  ·  Carcinoma, Hepatocellular (71)  ·  Stomach Neoplasms (69)  ·  Liver Neoplasms (54)  ·  Colonic Neoplasms (50)

Broader conditions

Digestive System Diseases (1022)  ·  Biliary Tract Diseases (1020)  ·  Pathological Conditions, Signs and Symptoms (397)  ·  Liver Diseases (359)  ·  Pathologic Processes (323)  ·  Neoplasms (291)  ·  Neoplasms by Site (287)  ·  Digestive System Neoplasms (283)  ·  Cholestasis (247)  ·  Cholestasis, Intrahepatic (237)  ·  Biliary Tract Neoplasms (232)  ·  Fibrosis (207)  ·  Liver Cirrhosis (203)  ·  Neoplasms by Histologic Type (192)

Interventions

Gemcitabine (41)  ·  Ursodeoxycholic Acid (36)  ·  Cholangiopancreatography, Endoscopic Retrograde (30)  ·  Cisplatin (24)  ·  fish oil triglycerides (23)  ·  Capecitabine (22)  ·  Fluorouracil (19)  ·  Oxaliplatin (17)  ·  maralixibat (16)  ·  obeticholic acid (15)  ·  Fenofibrate (14)  ·  Leucovorin (14)  ·  Vancomycin (13)  ·  Blood Specimen Collection (10)  ·  Cholecystectomy, Laparoscopic (10)

Sponsors

National Cancer Institute (NCI) (27)  ·  Mayo Clinic (24)  ·  Mirum Pharmaceuticals, Inc. (24)  ·  Gilead Sciences (17)  ·  Intercept Pharmaceuticals (14)  ·  Ipsen (12)  ·  Stanford University (12)  ·  Xijing Hospital of Digestive Diseases (12)  ·  GlaxoSmithKline (10)  ·  National Taiwan University Hospital (10)  ·  Assistance Publique - Hôpitaux de Paris (9)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (9)  ·  Children's Hospital Medical Center, Cincinnati (8)  ·  RenJi Hospital (8)  ·  Seoul National University Hospital (8)

Countries

United States (424)  ·  China (151)  ·  United Kingdom (97)  ·  Canada (96)  ·  Germany (85)  ·  France (84)  ·  Italy (68)  ·  South Korea (66)  ·  Spain (66)  ·  Belgium (49)  ·  Australia (46)  ·  Netherlands (38)  ·  Poland (38)  ·  Austria (27)  ·  Japan (27)

Top investigators

Ed Doo, MD (8)  ·  Michel Kahaleh, MD (8)  ·  Lisa Henn, PhD (6)  ·  John Magee, MD (5)  ·  Katrina Loh, MD (5)  ·  Li Yang, MD (5)  ·  Lynda Szczech, MD (4)  ·  Tim F Greten, M.D. (4)  ·  Averell Sherker, MD (3)  ·  Christopher L Bowlus, MD (3)  ·  Cynthia Levy, MD (3)

Results publications

PMID 25543678, PMID 38780109, PMID 42002216, PMID 17509029, PMID 19286178, PMID 23054338, PMID 26561627, PMID 26725209, PMID 28249726, PMID 29519540, PMID 29533266, PMID 29847616, PMID 29954008, PMID 30979521, PMID 31863440, PMID 32059815, PMID 32633158, PMID 32707155, PMID 32716060, PMID 33006765, PMID 33038344, PMID 34508767, PMID 34695449, PMID 35391541, PMID 37953500, PMID 38055647, PMID 38661512, PMID 40439725, PMID 41804276, PMID 42176183, PMID 10022591, PMID 10051462, PMID 10102814, PMID 10343514, PMID 10347106, PMID 10526025, PMID 10655252, PMID 11132910, PMID 11906641, PMID 12145577, PMID 12183720, PMID 12196376, PMID 12360466, PMID 12393999, PMID 1294807, PMID 15017671, PMID 15067627, PMID 15128074, PMID 15269615, PMID 15468571

NIH funding

2016 (7), 2019 (7), 2023 (7), U01DK062456 (7), 2014 (6), 2015 (6), U01DK062436 (5), U01DK062445 (5), U01DK062452 (5), U01DK062453 (5), U01DK062466 (5), U01DK062470 (5), U01DK062481 (5), U01DK062497 (5), U01DK062500 (5)